Eisai's lenvatinib to follow in Nexavar's footsteps?
This article was originally published in Scrip
Executive Summary
Lenvatinib, Eisai's next big oncology hope after breast cancer drug Halaven (eribulin), has met its primary endpoint in the Phase III SELECT trial in thyroid cancer patients. The company plans to submit marketing authorization applications for lenvatinib in the US, Japan and Europe based on these data.